Cleara is a biopharmaceutical R&D company dedicated to discovery and development of therapies against cancer and chronic diseases through selective elimination of specific subtypes of cellular senescence. Through detailed understanding of the molecular and biological pathways that underlie these individual pathological phenotypes, we set up disruptive, innovative and proprietary platform technology to design and optimize (peptide-based) therapeutics that exploit their weak spots for safe and selective clearance. Cleara’s lead FOXO4 program is focused on generation of disruptive and proprietary technology against “scarred” cellular senescence for treatment of metastatic, mutant-p53 cancer.